

Karin Jordan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2097824/publications.pdf>

Version: 2024-02-01

16
papers

1,434
citations

1040018

9
h-index

1058452

14
g-index

16
all docs

16
docs citations

16
times ranked

2035
citing authors

#	ARTICLE	IF	CITATIONS
1	Validation of a proxy-reported SARC-F questionnaire for current and retrospective screening of sarcopenia-related functional impairments. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2022, 13, 264-275.	7.3	6
2	Netupitant-palonosetron (NEPA) for Preventing Chemotherapy-induced Nausea and Vomiting: From Clinical Trials to Daily Practice. <i>Current Cancer Drug Targets</i> , 2022, 22, 806-824.	1.6	2
3	Practice Patterns for Prevention of Chemotherapy-Induced Nausea and Vomiting and Antiemetic Guideline Adherence Based on Real-World Prescribing Data. <i>Oncologist</i> , 2021, 26, e1073-e1082.	3.7	20
4	Carfilzomib, Lenalidomide, and Dexamethasone Followed by Salvage Autologous Stem Cell Transplant with or without Maintenance for Relapsed or Refractory Multiple Myeloma. <i>Cancers</i> , 2021, 13, 4706.	3.7	11
5	Local Radiation Therapy Before and During Induction Delays Stem Cell Mobilization and Collection in Multiple Myeloma Patients. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 876.e1-876.e11.	1.2	8
6	Is PFS the Right Endpoint to Assess Outcome of Maintenance Studies in Multiple Myeloma? Results of a Patient Survey Highlight Quality-of-Life As an Equally Important Outcome Measure. <i>Blood</i> , 2021, 138, 836-836.	1.4	6
7	Supplemental parenteral nutrition: decisions based on weak evidence. <i>ESMO Open</i> , 2020, 5, e000831.	4.5	1
8	How I treat cancer: treatment of rheumatological side effects of immunotherapy. <i>ESMO Open</i> , 2020, 4, e000529.	4.5	9
9	Impact of Novel Therapies on CD4-T-Cell-Numbers and Infectious Complications in Patients with Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2020, 136, 14-14.	1.4	0
10	Is the addition of a neurokinin-1 receptor antagonist beneficial in moderately emetogenic chemotherapy? a systematic review and meta-analysis. <i>Supportive Care in Cancer</i> , 2018, 26, 21-32.	2.2	22
11	Integration of oncology and palliative care: a Lancet Oncology Commission. <i>Lancet Oncology</i> , The, 2018, 19, e588-e653.	10.7	452
12	Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update. <i>Journal of Clinical Oncology</i> , 2017, 35, 3240-3261.	1.6	454
13	Supportive Treatments for Patients with Cancer. <i>Deutsches A&#x0308;rztblatt International</i> , 2017, 114, 481-487.	0.9	32
14	Antiemetics: American Society of Clinical Oncology Focused Guideline Update. <i>Journal of Clinical Oncology</i> , 2016, 34, 381-386.	1.6	173
15	International antiemetic guidelines on chemotherapy induced nausea and vomiting (CINV): Content and implementation in daily routine practice. <i>European Journal of Pharmacology</i> , 2014, 722, 197-202.	3.5	151
16	Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity state of the art. <i>Supportive Care in Cancer</i> , 2011, 19, 43-47.	2.2	87